Big Launch Year Coming Up In US For Sun But Spends High Too
Sun Pharma, India's top-ranked drug firm, has three key specialty launches lined up in the US in FY19. Management commentary was generally upbeat about the potential prospects of the three products, but also emphasized that the commercialization plans will entail significant costs.
You may also be interested in...
Sun’s now-approved higher concentration, quicker-acting formulation of cyclosporine A could offer competitive advantage in dry eye versus Allergan’s Restasis, but is it enough to offset lower costs of pending generic cyclosporines?
Sun Pharma acknowledged the intense competition that awaits its psoriasis asset, Ilumya (tildrakizumab) in the US, but maintained that the overall profile of the IL-23p19 inhibitor, which is expected to debut in Q2FY19, was “liked” by customers.
The latest drug development news and highlights from our US FDA Performance Tracker.